United Kingdom· GB-APID-35655911000001108
Qarziba 20mg/4.5ml concentrate for solution for infusion vials
A dinutuximab beta product containing dinutuximab beta, registered in United Kingdom by Recordati UK Ltd. The same ATC class is registered in 11 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Dinutuximab beta is registered in 11 of 19 countries.
Countries holding a registration under ATC L01FX06 (dinutuximab beta), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Dinutuximab beta · ATC L01FX06
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Dinutuximab beta
- Manufacturer
- Recordati UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01FX06
- ATC class
- Dinutuximab beta
- Defined daily dose
- 2.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin5060146291736
- gtin5060146293013
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
183 interactions on record for dinutuximab beta.
Graded by severity as the source publishes them — 54 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dinutuximab beta · interactions on record
183 records
- 54 severe
- 129 moderate
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dinutuximab beta in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandQarzibaAbacus Medicine A/S
- BelgiumQarziba 4.5 mg/mlRecordati Netherlands
- United StatesUnituxinUnited Therapeutics Corporation
- CzechiaQARZIBARecordati Netherlands B.V., Schiphol-Rijk
- SpainQARZIBA 4,5 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONRecordati Netherlands B.V.
- CanadaUNITUXINUNITED THERAPEUTICS CORPORATION
- FranceQARZIBA 4,5 mg/ml, solution à diluer pour perfusionRECORDATI IRELAND
- IrelandQarziba 4.5 mg/mL concentrate for solution for infusionEUSA Pharma (Netherlands) B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Qarziba
- Liechtenstein · Qarziba
- Norway · Qarziba
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/da9d3ce7-f86c-4b14-80cc-dba5e884af40 GET /v1/drugs/da9d3ce7-f86c-4b14-80cc-dba5e884af40?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "35655911000001108",
"desc": "Qarziba 20mg/4.5ml concentrate for solution for infusion vials (Recordati UK Ltd)",
"form": "Solution for infusion",
"vpid": "35655711000001106",
"source": "dmd",
"vtm_id": "35656111000001104",
"strength": "4.5 mg",
"substance": "Dinutuximab beta",
"ingredient": "Dinutuximab beta",
"supplier_code": "13210911000001103"
}See everything about dinutuximab beta.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.